Policy support accelerates the advancement of innovative drug R&D.
Release date:
2024-05-13
Recently, the General Office of the State Council issued the "Opinions on Comprehensively Deepening Drug and Medical Device Regulatory Reform to Promote High-Quality Development of the Pharmaceutical Industry," injecting strong momentum into the growth of the pharmaceutical sector.
Recently, the General Office of the State Council issued the "Opinions on Comprehensively Deepening Drug and Medical Device Regulatory Reform to Promote High-Quality Development of the Pharmaceutical Industry," injecting strong momentum into the growth of the pharmaceutical sector. The Opinions clearly state that by 2027, a regulatory system aligned with pharmaceutical innovation and industry development will be established, with review and approval resources increasingly tilted toward urgently needed, innovative drugs for clinical use. Throughout the entire process—ranging from clinical trials to registration submissions—regulatory authorities will enhance communication and collaboration with pharmaceutical companies, offering tailored guidance. This policy has greatly boosted the confidence of innovative drug firms. For instance, Hengrui Medicine’s independently developed hydroxyethyl sulfonyl darzalex tablets, in combination with endocrine therapy, achieved a significant breakthrough in the Phase III clinical trial for adjuvant treatment of HR-positive/HER2-negative breast cancer, markedly reducing the risk of disease recurrence. With supportive policies complemented by corporate innovation, more groundbreaking drugs are expected to accelerate their way to market, ultimately providing patients with a wider array of treatment options.
Related News
Company Address: Zone C, Specialized & Innovative Chemical Industry Incubation Base, West Section of Yili River Street, No. 436, Qinchuan Town, Qinchuan Park, Lanzhou New Area, Gansu Province
Mobile Phone Official Website